At the Hematology Center at Karolinska, we treat all forms of blood cancer and non-malignant hematological diseases, including hemophilia and mastocytosis. A wide range of treatments are administered, such as chemotherapy, immunotherapy, and autologous stem cell transplantation. To increase the potential of extended and improved life for patients with blood disorders, Karolinska focuses equally on healthcare, research, and education. Our goals are for all patients to feel safe and to get the best possible treatments, and we achieve this by offering top-quality care from our specialized team.
The Hematology Center at Karolinska is the largest of its kind in Sweden, and the collaboration between the center and the Karolinska Institutet ensures strong clinical and translational research. The clinical, experimental, and epidemiological environments facilitate internationally successful research.
The Coagulation Unit is a certified European Hemophilia Comprehensive Care Center (EHCCC) specializing in the diagnosis, treatment, and follow-up care of patients with hemophilia. We are a tertiary referral center and the largest hemophilia center in Sweden. Together with the Pediatric Coagulation Unit, we have a multidisciplinary team involving physicians, pediatricians, coagulation nurses, physiotherapists, social workers, psychologists, gynecologists, orthopedic surgeons, and orthopedic technicians. We have a close collaboration with the Special Coagulation Laboratory regarding diagnostics and monitoring. Apart from hemophilia, we diagnose and treat patients with other inherited or acquired bleeding or thromboembolic conditions in our outpatient clinic. Our Coagulation-doctor-on-call service handles over 20,000 consultations per year. We perform academic studies and clinical trials and have facilities for gene therapy. We are involved in national and international collaborations, including the Swedish Hemophilia Registry, Nordic Haemophilia Council, ISTH, and European Reference Networks (incl. EuroBloodNet and RECONNECT).
The hematology residency consists of two years of the common trunk in internal medicine and three years specializing in hematology. Karolinska has an extensive program for resident doctors, currently consisting of almost 20 colleagues completing their five years of residency. Resident physicians participate in all parts of the business under the supervision of a specialist and are given good opportunities to meet many patients with different diagnoses over a long time period. We have a very close collaboration with Medical Unit Cell Therapies and Allogeneic Stem Cell Transplantation (ME CAST), where all resident doctors have a placement. At CAST, our hematological patients in need of allogeneic stem cell transplantation or CAR-T cell therapy are treated. The goal for all resident doctors is to be active in some form of research work. We encourage all resident doctors to take the final exam for the hematology specialization, comprising a written exam, which, if passed, is followed by an oral exam in conjunction with the annual Swedish Hematology Society meeting.